First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Ligation of glucocorticoid-induced tumor necrosis factor receptor (GITR) decreases regulatory T cell-mediated suppression and enhances T-cell proliferation, effector function, and survival. MK-1248 is a humanized immunoglobulin G4 anti-GITR monoclonal antibody agonist. METHODS: In patients with advanced solid tumors, MK-1248 (starting dose, 0.12 mg) was tested alone and with pembrolizumab (200 mg) according to a 3 + 3 dose escalation design (ClinicalTrials.gov identifier NCT02553499); both treatments were administered intravenously every 3 weeks for ≤4 and ≤35 cycles, respectively. The safety and tolerability, maximum tolerated dose, and pharmacokinetics/pharmacodynamics were explored. RESULTS: Twenty patients received MK-1248 monotherapy; 17 received combination therapy. The most frequent tumor types were colorectal cancer (n = 8), melanoma (n = 6), and renal cell carcinoma (n = 4). MK-1248 was generally well tolerated at the maximum tested doses of 170 (monotherapy) and 60 mg (combination). No dose-limiting toxicities (DLTs) or treatment-related deaths occurred. Adverse events (AEs) occurred in 36 of the 37 patients (97%); the most common were vomiting (n = 13 [35%]), anemia (n = 10 [27%]), and decreased appetite (n = 10 [27%]). Grade 3 to 5 AEs occurred in 19 of the 37 patients (51%). Treatment-related AEs occurred in 18 of the 37 patients (49%): 9 of the 20 patients (45%) on monotherapy and 9 of the 17 patients (53%) on combination therapy. Among the 17 patients receiving combination therapy, 1 achieved a complete response and 2 achieved a partial response, for an objective response rate of 18%; no patients achieved an objective response with monotherapy. The disease control rate (stable disease or better) was 15% with monotherapy and 41% with combination therapy. CONCLUSIONS: MK-1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment-related deaths. Combination therapy provided limited antitumor responses.
Source: Cancer
DOI: 10.1002/cncr.33133
Authors: Ravit Geva(Data curation, Investigation, Resources, Validation, Writing – original draft, Writing – review & editing), Mark Voskoboynik(Data curation, Formal analysis, Investigation, Resources, Validation, Writing – review & editing), Konstantin Dobrenkov(Data curation, Formal analysis, Investigation, Validation, Writing – original draft, Writing – review & editing), Kapil Mayawala(Conceptualization, Formal analysis, Methodology, Validation, Writing – review & editing), Jennifer Gwo(Formal analysis, Resources, Validation, Writing – review & editing), Richard Wnek(Data curation, Formal analysis, Investigation, Validation, Writing – review & editing), Elliot Chartash(Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing), Georgina V. Long(Data curation, Investigation, Resources, Validation, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: pembrolizumab, immune checkpoint inhibitor combination, advanced solid tumors, first-in-human safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, regulatory T cells, colorectal cancer, melanoma, renal cell carcinoma, objective response rate, dose-limiting toxicity, anemia, vomiting
Open Access status: bronze
Funders: Merck, Merck Sharp and Dohme
OpenAlex ID: W3055519780
